Galectin Therapeutics Cash Flow - Quarterly (NASDAQ:GALT)

Add to My Stocks
$6.53 $0.4 (5.77%) GALT stock closing price Sep 21, 2018 (Closing)

The Galectin Therapeutics cash flow statement helps investors understand how well the company is managing its cash flows. This statement shows details about the cash generated and spent during a particular quarter, while the other two statements give details about Galectin Therapeutics profits and Galectin Therapeutics debt. Galectin Therapeutics had cash and cash equivalents of $15.36M at beginning of the quarter and $10.49M at quarter end of 2018 Q2. Galectin Therapeutics cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. Galectin Therapeutics had an outflow of $-6.59M from operating activities, $14.03M inflow due to financing activities, and $- outflow due to investing activities till 2018 Q2.

View and download details of Galectin Therapeutics cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
-8.09M-4.25M-16.23M-13.85M-9.44M-4.93M-21.43M-16.84M-12.31M-6.8M
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities-1.3M-0.53M-0.8M1M-0.03M-2.54M3.29M2.59M2.08M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net2.8M1.27M1.14M---2.47M2M1.62M1.22M
Net Cash from (used by) Operating Activities
-6.59M-3.51M-15.89M-11.98M-8.86M-3.86M-16.4M-11.54M-8.1M-3.49M
Increase (Decrease) in Prop Plant And Equipment----------
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
----------
Issuance (Purchase) of Equity Shares14.03M4.45M3.58M3.58M2.63M2.14M5.92M1.75M--
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
14.03M4.45M3.58M3.58M2.63M2.14M5.92M1.75M--
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
7.44M--12.3M-8.4M-6.23M-1.71M-10.48M-9.78M-7.84M-3.49M
Cash & Equivalents at Beginning of Year15.36M25.84M29.12M10.48M9.36M6.39M5.89M--1.31M
Cash & Equivalents at Year End10.49M3.98M3.05M6.95M9.12M13.64M15.36M16.05M18M22.35M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

While Galectin Therapeutics stock price history provides the price history of a stock, Galectin Therapeutics stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Galectin Therapeutics saw a positive change in Net Change in Cash and Cash Equivalents of $7.44M till 2018 Q2. Apart from the Galectin Therapeutics stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Galectin Therapeutics decreased its cash from operating activities to $-6.59M till 2018 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: Galectin Therapeutics used $- cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Galectin Therapeutics earned $14.03M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Galectin Therapeutics Cash Flow

Quarterly Cash Flow Statements For Galectin Therapeutics Inc Peers

Ardelyx cash flow, Enanta Pharma cash flow, Galmed Pharma cash flow, JOUNCE THERAPTC cash flow, MediciNova cash flow